Brokerages Set Claritev (NYSE:CTEV) PT at $33.67

Claritev (NYSE:CTEV) has been given an average rating of “Moderate Buy” by the seven research firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have issued a buy recommendation on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $33.6667.

A number of brokerages recently commented on CTEV. Citigroup reiterated a “buy” rating on shares of Claritev in a research report on Wednesday, May 13th. Wall Street Zen downgraded Claritev from a “hold” rating to a “sell” rating in a research report on Saturday, April 25th. UBS Group reiterated a “buy” rating on shares of Claritev in a research report on Tuesday, February 24th. Barclays began coverage on Claritev in a research report on Friday, April 24th. They set an “overweight” rating and a $28.00 price objective on the stock. Finally, Guggenheim reiterated a “buy” rating on shares of Claritev in a research report on Tuesday, February 24th.

Claritev Stock Performance

Shares of Claritev stock opened at $29.21 on Friday. Claritev has a one year low of $11.50 and a one year high of $74.07. The company has a market cap of $498.03 million, a price-to-earnings ratio of -1.69 and a beta of 0.77. The business’s 50 day moving average price is $24.19 and its 200 day moving average price is $25.86.

Institutional Investors Weigh In On Claritev

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. H&F Corporate Investors VIII Ltd. acquired a new stake in Claritev during the third quarter worth $285,988,000. Oak Hill Advisors LP acquired a new stake in Claritev during the third quarter worth $4,871,000. Topline Capital Management LLC acquired a new stake in Claritev during the third quarter worth $10,711,000. Citigroup Inc. acquired a new stake in Claritev during the third quarter worth $2,025,000. Finally, Arini Captial Management Ltd acquired a new stake in Claritev during the fourth quarter worth $64,291,000. Institutional investors and hedge funds own 87.15% of the company’s stock.

About Claritev

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.